Sarah L Pett, Moira Spyer, Lewis J Haddow, Ruth Nhema, Laura A Benjamin, Grace Najjuka, Sithembile Bilima, Ibrahim Daud, Godfrey Musoro, Juliet Kitabalwa, George Selemani, Salome Kandie, K Magut Cornelius, Chrispus Katemba, Jay A Berkley, Amin S Hassan, Cissy Kityo, James Hakim, Robert S Heyderman, Diana M Gibb, Ann S Walker
OBJECTIVES: To assess baseline prevalence of cryptococcal antigen (CrAg) positivity; and its contribution to reductions in all-cause mortality, deaths from cryptococcus and unknown causes, and new cryptococcal disease in the REALITY trial. DESIGN: Retrospective CrAg testing of baseline and week-4 plasma samples in all 1805 African adults/children with CD4+ cell count less than 100 cells/μl starting antiretroviral therapy who were randomized to receive 12-week enhanced-prophylaxis (fluconazole 100 mg/day, azithromycin, isoniazid, cotrimoxazole) vs...
March 15, 2021: AIDS